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Abstract
Our studies were aimed at developing a vaccination strategy that could provide protection against
highly pathogenic avian influenza virus (AIV), H7N3 or its variants outbreaks. A purified viral stock
of highly pathogenic H7N3 isolate was lysed to isolate viral proteins by electrophresing on 12%
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), followed by their elution
from gel through trituration in phosphate buffered  s a l i n e  ( P B S ) .  O v e r a l l ,  f i v e  i s o l a t e d  v i r a l
polypeptides/proteins upon characterization were used to prepare hyperimmune monovalent
serum against respective polypeptides independently and a mixture of all five in poultry birds, and
specificity confirmation of each antiserum through dot blot and Western blotting. Antiserum
generated from various group birds was pooled and evaluated in 2-week old broiler chicken, for
its protection against viral challenge. To evaluate in-vivo protection of each antiserum against viral
challenges, six groups of 2-week old broiler chicken were injected with antiserum and a seventh
control group received normal saline. Each group was exposed to purified highly pathogenic AIV
H7N3 strain at a dose 105 embryo lethal dose (ELD50). We observed that nucleoprotein (NP)
antiserum significantly protected birds from viral infection induced morbidity, mortality and
lowered viral shedding compared with antiserum from individual viral proteins or mixed
polypeptides/proteins inclusive of NP component. The capability of individual viral polypeptide
specific antisera to protect against viral challenges in decreasing order was nucleoprotein (NP) >
hemagglutinin (HA) > neuraminidase (NA) > viral proteins mix > viral polymerase (PM) > non-
structural proteins (NS). Our data provide proof of concept for potential utilization of passive
immunization in protecting poultry industry during infection outbreaks. Furthermore conserved
nature of avian NP makes it an ideal candidate to produce antiserum protective against viral
infection.
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Background
Avian influenza virus (AIV) besides reducing commercial
production of poultry is also a causative agent for influ-
enza among humans by cross-species infections [1]. The
viral genome encodes 10 proteins and among these two
surface proteins haemagglutinin and neuraminidase have
main importance in viral classification [2]. AIV grouping
is based on antigenic variations in haemagglutinin (H1 –
H16) and neuraminidase (N1 – N9) proteins and each
strain of virus is named based on respective H and N anti-
genicity [3]. According to virulence pattern in poultry, the
AIV is mainly classified into two major groups: highly
pathogenic avian influenza (HPAI) and low pathogenic
avian influenza (LPAI). The HPAI strains are highly viru-
lent and associated with bird mortality approaching
100%, whereas LPAI viruses manifest mild symptoms like
decreased egg production and scruffy feathers. Through-
out the world majority of avian influenza epidemics are
due to HPAI viruses showing H5 and H7 antigenicity
[4,5]. In Pakistan, low pathogenic H9N2 along-with high
pathogenic H7N3 and H5N1 are the most predominant
AIV strains and several outbreaks over the past decades are
ascribed to these particular strains [6-8].
Avian influenza (AI) has emerged as a disease with signif-
icant potential to disrupt commercial poultry production,
resulting in heavy losses to poultry farmers in several parts
of the world. Due to fastidious viral genome, conven-
tional antivirals against AIV are unable to control the
infection and very few effective vaccines are available.
Moreover, geographic strain variations have made it diffi-
cult to implement universal avian influenza vaccine strat-
egy. As such, there has been an urgent need to develop
broad spectrum antivirals against AIV or vaccines capable
of coping with viral genomic changes. One of the most
plausible options to control AI is development of regional
immunization programs against the serotype involved in
an outbreak. However, as the immunization has to be car-
ried out prior to disease for establishing therapeutic levels
of antibodies against the infection, in case of its sudden
outbreak such control measures are not possible. Passive
immunization has emerged as an effective therapeutic
tool in the face of an outbreak; however its effectiveness in
the case of AIV has not yet been investigated. During past
decade, AIV, H7 serotype has caused high poultry birds
mortality in different countries including Pakistan [6].
The whole virus killed AIV vaccines used against H7 has
been found to be effective in reducing the clinical condi-
tions of the birds upon subsequent field challenge [2].
However, practically it is always difficult to make use of
any kind of killed vaccines during the outbreaks due to
very short incubation period associated with highly path-
ogenic AI infection. Keeping this in view, the present study
was designed to compare various viral proteins for their
potentials as a vaccine candidate. According to our data
nucleoprotein (NP) antiserum significantly protected
birds from viral infection induced morbidity/mortality
and lowered viral shedding compared with antiserum
from other viral proteins like hemagglutinin (HA) neu-
raminidase (NA), viral polypeptides mix, non structural
protein and viral polymerase enzyme. This proof of con-
cept study provides initial data to rely on utilization of
individual viral protein for passive immunization pro-
grams.
Results
Our initial work on SDS-PAGE analysis of H7N3 viral
lysate showed five major viral proteins: high molecular
weight polymerase (PM), hemagglutinin (HA), nucleo-
protein (NP), neuraminidase (NA) and non-structural
protein (NS) as shown in Figure 1. These polypetides were
further concentrated and subjected to electrophoresis on
SDS-PAGE. Five obvious bands of AIV viral polypetides
were cut from the gel, triturated and diluted with 1.0 ml
of normal saline. This follows generation of polypeptide
specific antibodies against each polypeptide and also a
mixture of all was used to generate antisera. The specificity
of each polypeptide antiserum was confirmed by Dot-
ELISA. Intriguingly, the viral peptides mix antisera
detected H7N3 viral particles at 1:4 dilution (Figure 2).
All the birds used in this study were confirmed negative
against AIV H7N3 antibodies by HI test. Passive immuni-
zation with individual polypeptide/protein specific antis-
era followed challenge with highly pathogenic AIV,
H7N3. After 48 hours birds immunized with antisera and
non-immunized control group were challenged with 0.2
ml of H7N3 viral strain A/Chicken/Pakistan/Murree/
NARC/69/04 (H7N3). Birds' morbidity, mortality and
cloacal shedding were observed over a time period of two-
week. Four out of the six vaccinated group showed protec-
SDS-PAGE analysis of avian influenza Virus strain H7N3 pro- teins Figure 1
SDS-PAGE analysis of avian influenza Virus strain 
H7N3 proteins. Five major viral proteins are marked on gel 
corresponding to their molecular weight ascertained through 
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tion from lethal viral challenge whereas negative control
group showed highest level of mortality, morbidity and
cloacal shedding. The level of protection in the four
groups varied and nucleoprotein antiserum vaccinated
group birds showed highest protection revealed by least
mortality, and low viral shedding (60%). The birds pas-
sively immunized with polymerase and non-structural
protein antiserum showed no protection at all. Upon viral
challenge, seven out of ten birds died in polymerase and
non-structural protein antiserum vaccinated groups,
whereas eight in non-vaccinated control group (Table 1).
This trend continued and on day 4th all the birds in PM,
NS and control (normal saline group) were dead. Mortal-
ity was associated with extensive morbidity in polypep-
tides groups showing less protection. One of the groups
was vaccinated with antiserum generated from a mixture
of all five peptides (viral polypeptides mix group). It was
intriguing to note that on day 4th two birds died in this
group without any further mortality thus showing 80%
protection. No mortality (100% protection) was observed
in birds pre-vaccinated with hemagglutinin, nucleopro-
tein, and neuraminidase antisera. However, morbidity
and viral shedding revealed 80–100% birds infected in
HA vaccinated group, 20 – 60% in NP and 80–100% in
NA groups (Table 1).
Morbidity describes disease condition and prevalence of
various symptoms associated with viral infection in birds.
In case of bird flu outbreak, the infected birds manifest
quite distinctive symptoms like ruffled feathers, excessive
thirst, areas of diffuse hemorrhage between the hocks and
feet, edema surrounding the eyes, watery green diarrhea
progressing to white and several others. Mortality in the
control (non-vaccinated) and two of the viral peptides
(PM, NS) antisera manifesting least protection (0%) was
associated with several disease symptoms an indicator for
high morbidity (100%). In comparing the data of all pro-
tective antisera groups, the level of morbidity was higher
in viral polypeptides and neuraminidase groups (100%)
followed by hemagglutinin (80%) on day 4th. The nucle-
oprotein antiserum immunized group showed the least
morbidity (maximum 60%) at day 4 along-with no mor-
tality (0%) and lowest level of cloacal shedding makes it
a potential candidature for poultry vaccine against H7N3
especially through passive immunization route.
In vaccinated groups challenged with lethal AIV, NP
groups showed least cloacal shedding of virus among all
the groups. All other vaccinated and non-vaccinated con-
trol manifested cloacal shedding of virus. These data are
quite interesting and will help us in designing future vac-
cine for AIV in poultry.
Discussion
Infections associated with AIV are threatening economy of
several countries throughout the World. Particularly in
South-East Asia viral infection has inflicted major losses to
poor poultry farm holders as well as it poses a threat of
cross-species infection among humans. AIV is a member
of Type A group viruses and compared with its counter-
parts Type B and C has broad host range capable of caus-
ing infections in several birds and mammals. One of the
major threats of AIV has been its capability to cross-spe-
cies jumping i.e. from birds to humans [9].
According to a report from the International Federation
for Animal Health (IFAH) vaccination strategies for con-
trolling AIV infection in birds is one of the major viable
options compared with other control measures [10]. Sev-
eral vaccine strategies including production of vaccine
from virus like particles are on horizon [11,12]. Killed vac-
cines have also been considered to control viral pandemic
in flocks in-spite of its limitation in surveillance programs
involving differentiation of infected from vaccinated ani-
mals (DIVA) test [2] particularly if killed vaccines are
being used. For differentiating vaccinated birds from the
naturally infected ones DIVA test strategy relies on detect-
ing antibodies against N-type only found in infected birds
and not against serotype of vaccine strain, besides general
monitoring strategy of unvaccinated sentinels.
Passive immunization with antiserum generated from
viral polypeptides antigenic determinants has shown sig-
nificant protection in mammals [13,14] and also in birds
[15]. We employed a passive immunization strategy by
utilizing various proteins of AIV to ascertain which one of
Dot-ELISA Figure 2
Dot-ELISA. confirms the antiserum specificity against 
respective polypetide.V
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Table 1: Protection of vaccinated poultry birds against highly pathogenic AIV H7N3 strain
Groups Antisera against viral 
protein(s)
Post-challenge mortality at different days Post-challenge morbidity at different days Post-challenge cloacal shedding at different days
247 1 4 2 47 1 42 4 71 4
1 Viral polymerase 7/10 10/10 -- -- 3/10 -- -- -- 3/10 -- -- --
2 Hemagglutinin 0/10 0/10 0/10 0/10 4/10 8/10 8/10 0/10 10/10 10/10 8/10 2/10
3 Nucleoprotein 0/10 0/10 0/10 0/10 2/10 6/10 5/10 0/10 6/10 6/10 5/10 0/10
4 Neuraminidase 0/10 0/10 0/10 0/10 9/10 10/10 8/10 0/10 10/10 10/10 8/10 3/10
5 Non-structural protiens 7/10 10/10 -- -- 3/10 -- -- -- 3/10 -- -- --
6 Viral polypeptides mixed 0/10 2/10 0/8 0/8 10/10 8/8 7/8 0/8 10/10 8/8 7/8 2/8
7 Normal saline 8/10 10/10 -- -- 2/10 -- -- -- 2/10 -- -- --Virology Journal 2008, 5:144 http://www.virologyj.com/content/5/1/144
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these could be comparatively a better candidate for the
generation of antisera to be used for passive immuniza-
tion. The viral polypeptides used in this study were from
a highly pathogenic avian influenza virus serotype H7N3
that has been previously reported in Pakistan and several
other parts of the world [6,7,16]. Our proof of concept
studies reveal that it is possible to develop passive immu-
nization strategies against AIV subtype by using viral pro-
teins and among the five viral proteins (hemagglutinin,
neuraminidase, nucleoproteins, non-structural protein,
polymerase, and a mixture of all these) nucleoprotein
generated antiserum provided better protection in birds
upon challenge with highly pathogenic avian influenza
virus.
Four out of six vaccines have given protection in decreas-
ing order NP>HA>NA>viral polypeptides mix. In case of
HA, NA and viral polypeptides mix, the level of infection
increased from day 0 to day 4 and then it decreased till the
end of experiment i.e. day 14. NP antiserum besides pro-
viding 100% protection also boosted chick's immunity
manifested as sustained resistance against infection (low
level of morbidity and viral shedding) as compared to
other vaccine groups. These data suggest that passively
transfused anti-NP antibodies have a better antiviral neu-
tralizing effect and overall protection from AIV. Overall, a
better protection provided during days 7–14 is due to
immune regulation.
Considering the situation of developing nations like Paki-
stan passive immunization strategy will be economical
and targeted. Avian Influenza is capable of changing anti-
genic determinants that leads to inefficacy of vaccines. A
locally produced economical vaccine will provide effec-
tive and long lasting solution to this pandemic especially
the non-variant parts (nucleoproteins) that hold the
promising future of AIV vaccines.
Materials and methods
Prior to beginning this study the protocol was reviewed
and approved by the animal biosafety committee of the
Pir Mehr Ali Shah Arid Agriculture University Rawalpindi,
and all the viral challenges and preparations were con-
ducted at the biosecure facilities of the National Reference
Laboratory for Poultry Diseases (NRLPD) at the Animal
Sciences Institute, National Agriculture Research Center
(NARC), Islamabad, Pakistan.
Viral stocks
A previously isolated highly pathogenic AIV serotype
H7N3 A/Chicken/Pakistan/Murree/NARC/69/04 (H7N3)
[17] was obtained from the repository of the NRLPD at
Animal Sciences Institute, National Agricultural Research
Center (NARC), Islamabad. The viral stock was reactivated
in the allantoic cavity of embryonated hen's eggs as
described previously [18]. Agar gel precipitation test was
used to confirm the presence of AIV in the allantoic fluid
[19] and HA test was performed to calculate the viral titer,
whereas embryo lethal dose 50 (ELD50) titer of the fresh
viral stock was determined by classical Reed and Muench
[20] methodology. In brief, this involves 10 fold serial
dilutions of stock virus in normal saline (101 to 1012) fol-
lowed by injecting 0.2 ml of each dilution into the chori-
oallantoic region of embryonated eggs. The mortality of
eggs is recorded and ELD50 calculated as described previ-
ously[20].
Preparation of viral polypeptides and production of 
monovalent hyperimmune antisera
Purified fresh stock of H7N3 AIV was lysed with 4% Triton
X-100 using 0.01 M Tris buffer (pH 7.2) in the presence of
1 mM KCl. Viral lysate was stirred for 45 minutes at room
temperature followed by centrifugation at 10,000 × g to
get the supernatant containing HA, NA and matrix (M)
proteins. The pellet containing NP protein was washed
with phosphate buffer saline (PBS), by re-centrifuging at
10,000 × g for 1 hour at 4°C. To remove viral DNA/viral
particles the supernatant was centrifuged at 200,000 × g
by using Beckman ultracentrifuge L8-80 on 50 Ti rotor
(Beckman, USA) for 1 hour to remove the viral DNA and
viral particles. The supernatant was collected and dialyzed
against 0.01 M PBS for 48 hours. It was again centrifuged
at 10,000 × g for 10 minutes to separate M protein out of
these preparations and the resulting pellet was suspended
in PBS. The supernatant containing HA, NA, polymerase
(PM) and non-structural (NS) proteins was collected by
centrifuging three times repeatedly at 10,000 × g for 10
minutes at 4°C. The supernatants were dialyzed and the
resultant collections were analyzed on 12% polyacryla-
mide gel. Five bands of AIV proteins separated on the gel
were cut, triturated and diluted with 1 ml of normal saline
solution (NSS). The material was centrifuged at 1000 × g
for 10 min and supernatant was quantified by Lowry's
method [21]. Each polypeptide was emulsified with com-
plete Freund's adjuvant and injected @ 4 μg/bird/injec-
tion via subcutaneous route in six groups of four birds
each (fourth bird was a negative control), twice at two
weeks interval, respectively.
Dot-ELISA
Dot-ELISA was standardized and performed to check the
specificity of each polypeptide specific antisera against AI
H7N3 virus. Antigen dots were used in different dilutions
ranging from Neat virus to 1:4 dilutions with NSS along
with a dot containing BSA as a negative control.
Passive immunization with polypeptides specific antisera
Broiler chicks tested negative for AIV were divided equally
into seven group of ten each. These birds were reared
under strict isolation and high security conditions inPublish with BioMed Central    and   every 
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chicken isolators. At the age of two weeks, birds were pas-
sively immunized with 4 ml each of the polypeptide spe-
cific antisera. Birds were challenged while rearing in
chicken isolators at 24 hours post inoculation (PI) with
live virus of AI serotype H7N3 at a dose 105 ELD50. The
birds were examined for clinical signs, mortality and cloa-
cal shedding, up to 14 days post-challenge (PC).
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